Redeye comments on AlzeCure Pharma presenting new preclinical data for NeuroRestore ACD856 at the AD/PD Conference in Copenhagen (17–21 March 2026). The presentation provides deeper mechanistic validation and reinforces the asset’s potential in multiple CNS indications.
LÄS MER